Statistical Significance

Clinical Roundup: Cardiff, VYNE and NewAmsterdam Report Key Trial Results in Multiple Disease Areas

4 weeks ago talkbio0Tagged Alzheimer 's disease, BROADWAY trial, Cardiff Oncology, Clinical Trials, Metastasis from malignant neoplasm of colon and/or rectum, Neoplasms, NewAmsterdam Pharma, onvansertib, Statistical Significance, Vyne

Cardiff Oncology; VYNE; NewAmsterdam Pharma; clinical trial updates; onvansertib; metastatic colorectal cancer; Alzheimer’s disease; BROADWAY trial; oncology; statistically significant results

Bristol Myers’ schizophrenia drug Cobenfy stumbles as adjunctive treatment, denting blockbuster plan

4 months ago talkbio0Tagged Adjunctive Orthodontic Procedure, Antipsychotic Agents, Cobenfy, Improvement, Myers, Schizophrenia, Single Agent Therapy, Statistical Significance

Cobenfy, Schizophrenia, Antipsychotic Agents, Adjunctive Orthodontic Procedure, Myers, Statistical Significance, Improvement, Single Agent Therapy

Transcend’s neuroplastogen posts positive mid-stage results in PTSD

5 months ago talkbio0Tagged CAPS-5, Placebos, Post-Traumatic Stress Disorder, Statistical Significance, TSND-201

TSND-201, Post-Traumatic Stress Disorder, Placebos, Statistical Significance, CAPS-5

Mixed pivotal data for Pfizer, Arvinas’ protein degrader in breast cancer

6 months ago talkbio0Tagged Clinical Trials, ESR1 gene, Improvement, Market, Pfizer, Progression-Free Survival, Statistical Significance, Vepdegestrant

Pfizer, Vepdegestrant, Clinical Trials, ESR1 gene, Statistical Significance, Improvement, Progression-Free Survival, Market

Lexicon stumbles on second batch of mixed results for pain drug

6 months ago talkbio0Tagged Dosage, lexicon, Statistical Significance

Dosage, lexicon, Statistical Significance

Oculis Announces Phase 2 Results for Licaminlimab in Dry Eye Disease, Despite Limited Statistical Significance

1 year ago talkbio0Tagged Dry Eye Syndromes, Licaminlimab, Oculis, Phase 2, Statistical Significance

Oculis, Licaminlimab, Dry Eye Disease, Phase 2 Results, Statistical Significance

Intra-Cellular’s Caplyta Triumphs in Major Depressive Disorder Phase 3 Trial, Edging Closer to FDA Filing

1 year ago talkbio0Tagged Caplyta, CGI-S, Clinical Global Impression Original Version Questionnaire, clinically, File (record), Intra-Cellular Therapies, Lumateperone, MADRS, MDD, Montgomery-Åsberg depression rating scale, Phase 3 trial, Positive, results, Severities, Statistical Significance, Unipolar Depression, United States Food and Drug Administration

Intra-Cellular Therapies, Caplyta, Lumateperone, Major Depressive Disorder (MDD), Phase 3 Trial, Positive Results, Statistically Significant, Clinically Meaningful, Montgomery-Åsberg Depression Rating Scale (MADRS), Clinical Global Impression Scale for Severity of Illness (CGI-S), FDA Filing

Amylyx’s ALS Treatment Relyvrio Disappoints in Phase III PHOENIX Study, Company Considering Market Withdrawal

1 year ago talkbio0Tagged Amylyx, Amyotrophic Lateral Sclerosis, Clinical Trials, Failure (biologic function), Market, Phase III PHOENIX Study, Placebos, Relyvrio, Statistical Significance, Withdraw (activity)

Amylyx, Relyvrio, ALS, Failure, Phase III PHOENIX Study, Market Withdrawal, Clinical Trial, Placebo, No Statistical Significance

Akero Reinforces Phase III FGF21 Analog Candidate with Enhanced Fibrosis Response Rates in MASH Data Update

1 year ago talkbio0Tagged Analog, Antibody-Drug, Efruxifermin, fibroblast growth factor 21, Fibrosis Response Rate, Improvements, metabolic dysfunction-associated steatohepatitis, Phase IIb HARMONY Study, Statistical Significance

Akero Therapeutics, FGF21 Analog, efruxifermin (EFX), Metabolic Dysfunction-Associated Steatohepatitis (MASH), Phase IIb HARMONY Study, Fibrosis Response Rate, 96 Weeks, Statistically Significant Improvements